Helius Medical Technologies, Inc. (HSDT)
Chart Events
Performance Outlook
| Previous Close | 1.5000 |
| Open | 1.5100 |
| Bid | 1.1000 x 800 |
| Ask | 1.5400 x 1100 |
| Day's Range | 1.4350 - 1.5100 |
| 52 Week Range | 1.0600 - 17.2600 |
| Volume | |
| Avg. Volume | 29,819 |
| Market Cap | 5.156M |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.1600 |
| Earnings Date | Mar 08, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- GlobeNewswire
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NEWTOWN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 23, 2022, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to four individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeutic Experience Program
-- Second Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis --NEWTOWN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Shepherd Center in Atlanta, Georgia to its Therapeutic Experien
- GlobeNewswire
Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®
-- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing -- NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended March 31, 2022. First Quarter and Recent Business Updates U.S. commercial launch of PoNS® for multiple sclerosis (“MS”) commenced with 23 prescriptions written and 2 filled.Finaliz
